Clinical efficacy of complement C5a inhibition by IFX‐1 in hidradenitis suppurativa: an open‐label single‐arm trial in patients not eligible for adalimumab

Autor:	I. Otto, R. Guo, Theodora Kanni, Themistoklis N. Spyridopoulos, N. Riedemann, Evangelos J. Giamarellos-Bourboulis, M. Argyropoulou, O. Zenker
Rok vydání:	2020
Předmět:	medicine.medical_specialty business.industry MEDLINE Complement C5a Dermatology medicine.disease Text mining Adalimumab medicine In patient Hidradenitis suppurativa Clinical efficacy Open label business medicine.drug
Zdroj:	British Journal of Dermatology. 183:176-178
ISSN:	1365-2133 0007-0963
DOI:	10.1111/bjd.18877
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4a5f5d641c139b5c2592aa4f0ac703c8 https://doi.org/10.1111/bjd.18877 Zobrazit plný text záznamu Plný text